The emerging role of the gut mycobiome in liver diseases

References

• Norman JM, Handley SA, Virgin HW. Kingdom-agnostic metagenomics and the importance of complete characterization of enteric microbial communities. Gastroenterology. 2014;146:1459–15.
   PubMed Web of Science ®Google Scholar
• Wang B, Yao M, Lv L, Ling Z, Li L. The human microbiota in health and disease. Engineering. 2017;3:71–82.
   Web of Science ®Google Scholar
• Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R, Angenent LT, Ley RE. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A. 2011;108:4578–4585.
   PubMed Web of Science ®Google Scholar
• Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–227.
   PubMed Web of Science ®Google Scholar
• Kim YS, Unno T, Kim B-Y, Park M-S. Sex differences in gut microbiota. World J Mens Health. 2020;38:48.
   PubMedGoogle Scholar
• Valeri F, Endres K. How biological sex of the host shapes its gut microbiota. Front Neuroendocrinol. 2021;61:100912.
   PubMed Web of Science ®Google Scholar
• Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105–108.
   PubMed Web of Science ®Google Scholar
• Claesson MJ, Jeffery IB, Conde S, Power SE, O’Connor EM, Cusack S, Harris HMB, Coakley M, Lakshminarayanan B, O’Sullivan O, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012;488(7410):178–184.
   PubMed Web of Science ®Google Scholar
• Walker RL, Vlamakis H, Lee JWJ, Besse LA, Xanthakis V, Vasan RS, Shaw SY, Xavier RJ. Population study of the gut microbiome: associations with diet, lifestyle, and cardiometabolic disease. Genome Med. 2021;13:188.
   PubMed Web of Science ®Google Scholar
• Zhong H, Penders J, Shi Z, Ren H, Cai K, Fang C, Ding Q, Thijs C, Blaak EE, Stehouwer CDA, et al. Impact of early events and lifestyle on the gut microbiota and metabolic phenotypes in young school-age children. Microbiome. 2019;7(1):2.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Dollive S, Grunberg S, Chen J, Li H, Wu GD, Lewis JD, Bushman FD. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLos One. 2013;8:e66019.
   PubMed Web of Science ®Google Scholar
• Morales P, Brignardello J, Gotteland M. The association of intestinal microbiota with obesity. Rev Med Chil. 2010;138:1020–1027.
   PubMed Web of Science ®Google Scholar
• Borges FM, de Paula TO, Sarmiento MRA, de Oliveira MG, Pereira MLM, Toledo IV, Nascimento TC, Ferreira-Machado AB, Silva VL, Diniz CG. Fungal diversity of human gut microbiota among eutrophic, overweight, and obese individuals based on aerobic culture-dependent approach. Curr Microbiol. 2018;75:726–735.
   PubMed Web of Science ®Google Scholar
• Li WZ, Stirling K, Yang JJ, Zhang L. Gut microbiota and diabetes: from correlation to causality and mechanism. World J Diabetes. 2020;11:293–308.
   PubMed Web of Science ®Google Scholar
• Chen Z, Radjabzadeh D, Chen L, Kurilshikov A, Kavousi M, Ahmadizar F, Ikram MA, Uitterlinden AG, Zhernakova A, Fu J, et al. Association of insulin resistance and type 2 diabetes with gut microbial diversity: a microbiome-wide analysis from population studies. JAMA Netw Open. 2021;4(7):e2118811.
   PubMed Web of Science ®Google Scholar
• Gupta VK, Cunningham KY, Hur B, Bakshi U, Huang H, Warrington KJ, Taneja V, Myasoedova E, Davis JM, Sung J. Gut microbial determinants of clinically important improvement in patients with rheumatoid arthritis. Genome Med. 2021;13:149.
   PubMed Web of Science ®Google Scholar
• Manasson J, Blank RB, Scher JU. The microbiome in rheumatology: where are we and where should we go? Ann Rheum Dis. 2020;79:727–733.
   PubMed Web of Science ®Google Scholar
• Fattorusso A, Di Genova L, Dell’isola GB, Mencaroni E, Esposito S. Autism spectrum disorders and the gut microbiota. Nutrients. 2019;11:E521.
   PubMed Web of Science ®Google Scholar
• Lou M, Cao A, Jin C, Mi K, Xiong X, Zeng Z, Pan X, Qie J, Qiu S, Niu Y, et al. Deviated and early unsustainable stunted development of gut microbiota in children with autism spectrum disorder. Gut. 2022;71:1588–1599. gutjnl-2021-325115.
   PubMed Web of Science ®Google Scholar
• Mulle JG, Sharp WG, Cubells JF. The gut microbiome: a new frontier in autism research. Curr Psychiatry Rep. 2013;15:337.
   PubMed Web of Science ®Google Scholar
• Akbar N, Khan NA, Muhammad JS, Siddiqui R. The role of gut microbiome in cancer genesis and cancer prevention. Health Sci Rev. 2022;2:100010.
   Google Scholar
• Lee KA, Luong MK, Shaw H, Nathan P, Bataille V, Spector TD. The gut microbiome: what the oncologist ought to know. Br J Cancer. 2021;125:1197–1209.
   PubMed Web of Science ®Google Scholar
• Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151–171.
   PubMed Web of Science ®Google Scholar
• Li X, Shen J, Ran Z. Crosstalk between the gut and the liver via susceptibility loci: novel advances in inflammatory bowel disease and autoimmune liver disease. Clin Immunol Orlando Fla. 2017;175:115–123.
   PubMed Web of Science ®Google Scholar
• Atif M, Warner S, Oo YH. Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells. Hepatol Int. 2018;12:305–314.
   PubMed Web of Science ®Google Scholar
• Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020;72:558–577.
   PubMed Web of Science ®Google Scholar
• Llorente C, Schnabl B. The Gut Microbiota and Liver Disease. Cell Mol Gastroenterol Hepatol. 2015;1:275–284.
   PubMed Web of Science ®Google Scholar
• Ilan Y. Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis. World J Gastroenterol: WJG. 2012;18:2609–2618.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhan H, Xu W, Yan S, Ng SC. The role of gut mycobiome in health and diseases. Ther Adv Gastroenterol. 2021;14:17562848211047130.
   Web of Science ®Google Scholar
• Pérez JC. Fungi of the human gut microbiota: roles and significance. Int J Med Microbiol. 2021;311:151490.
   PubMed Web of Science ®Google Scholar
• Wu X, Xia Y, He F, Zhu C, Ren W. Intestinal mycobiota in health and diseases: from a disrupted equilibrium to clinical opportunities. Microbiome. 2021;9:60.
   PubMed Web of Science ®Google Scholar
• Nash AK, Auchtung TA, Wong MC, Smith DP, Gesell JR, Ross MC, Stewart CJ, Metcalf GA, Muzny DM, Gibbs RA, et al. The gut mycobiome of the human microbiome project healthy cohort. Microbiome. 2017;5(1):153.
   PubMedGoogle Scholar
• Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14:e1002533.
   PubMed Web of Science ®Google Scholar
• Auchtung TA, Fofanova TY, Stewart CJ, Nash AK, Wong MC, Gesell JR, Auchtung JM, Ajami NJ, Petrosino JF. Investigating colonization of the healthy adult gastrointestinal tract by fungi. mSphere. 2018;3(2): e00092-18.
   PubMed Web of Science ®Google Scholar
• Shuai M, Fu Y, Zhong H-L, Gou W, Jiang Z, Liang Y, Miao Z, Xu J-J, Huynh T, Wahlqvist ML, et al. Mapping the human gut mycobiome in middle-aged and elderly adults: multiomics insights and implications for host metabolic health. Gut. 2022 January;71(9): gutjnl-2021-326298.
   PubMed Web of Science ®Google Scholar
• Richard ML, Sokol H. The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. 2019;16:331–345.
   PubMed Web of Science ®Google Scholar
• Hallen-Adams HE, Suhr MJ. Fungi in the healthy human gastrointestinal tract. Virulence. 2017;8:352–358.
   PubMed Web of Science ®Google Scholar
• Szóstak N, Handschuh L, Samelak-Czajka A, Tomela K, Schmidt M, Pruss Ł, Milanowska-Zabel K, Kozlowski P, Philips A. Host factors associated with gut mycobiome structure. mSystems. 2023 February;8(2):e0098622.
   PubMed Web of Science ®Google Scholar
• Odds FC. Candida infections: an overview. Crit Rev Microbiol. 1987;15:1–5.
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Nguyen MH. Systemic Candidiasis: Candidemia and Deep-Organ Infections. In: Calderone RA, Clancy CJ, editors. Candida and Candidiasis. Washington, DC, US: ‎ASM Press; 2012. p. 429–441. doi:10.1128/9781555817176.
   Google Scholar
• Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H. Alcoholic liver disease. Nat Rev Dis Primer. 2018;4:16.
   PubMed Web of Science ®Google Scholar
• Sheron N. Alcohol and liver disease in Europe–simple measures have the potential to prevent tens of thousands of premature deaths. J Hepatol. 2016;64:957–967.
   PubMed Web of Science ®Google Scholar
• Llopis M, Cassard AM, Wrzosek L, Boschat L, Bruneau A, Ferrere G, Puchois V, Martin JC, Lepage P, Le Roy T, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut. 2016;65(5):830–839.
   PubMed Web of Science ®Google Scholar
• Yang A-M, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, Bluemel S, Hartmann P, Xu J, Koyama Y, et al. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017;127(7):2829–2841.
   PubMed Web of Science ®Google Scholar
• Kankkunen P, Teirilä L, Rintahaka J, Alenius H, Wolff H, Matikainen S. (1,3)-β-glucans activate both dectin-1 and NLRP3 inflammasome in human macrophages. J Immunol. 2010;184:6335–6342.
   PubMed Web of Science ®Google Scholar
• Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, Barrieau M, Min SY, Kurt-Jones EA, Szabo G. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest. 2012;122:3476–3489.
   PubMed Web of Science ®Google Scholar
• Li X, Ma L, Zhang L. Chapter twelve - molecular basis for poria cocos mushroom polysaccharide used as an antitumor drug in China. In: Zhang L, editor. Progress in molecular biology and translational science. Vol 163. Glycans and glycosaminoglycans as clinical biomarkers and therapeutics - part B. Academic Press; 2019 [Accessed June 27, 2022]. pp. 263–296. https://www.sciencedirect.com/science/article/pii/S1877117319300328.
   Google Scholar
• Sun S, Wang K, Sun L, Cheng B, Qiao S, Dai H, Shi W, Ma J, Liu H. Therapeutic manipulation of gut microbiota by polysaccharides of wolfiporia cocos reveals the contribution of the gut fungi-induced PGE2 to alcoholic hepatic steatosis. Gut Microbes. 2020;12:1830693.
   PubMed Web of Science ®Google Scholar
• Hartmann P, Lang S, Zeng S, Duan Y, Zhang X, Wang Y, Bondareva M, Kruglov A, Fouts DE, Stärkel P, et al. Dynamic changes of the fungal microbiome in alcohol use disorder. Front Physiol. 2021;12:699253.
   PubMed Web of Science ®Google Scholar
• Chu H, Duan Y, Lang S, Jiang L, Wang Y, Llorente C, Liu J, Mogavero S, Bosques-Padilla F, Abraldes JG, et al. The candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. J Hepatol. 2020;72(3):391–400.
   PubMed Web of Science ®Google Scholar
• Lang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura‐cots M, Abraldes JG, Bosques‐padilla F, Verna EC, Brown RS, et al. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatol Baltim Md. 2020;71(2):522–538.
   PubMed Web of Science ®Google Scholar
• Drummond RA, Desai JV, Ricotta EE, Swamydas M, Deming C, Conlan S, Quinones M, Matei-Rascu V, Sherif L, Lecky D, et al. Long-term antibiotic exposure promotes mortality after systemic fungal infection by driving lymphocyte dysfunction and systemic escape of commensal bacteria. Cell Host & Microbe. 2022 May;30(7):1020–1033.e6.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
   PubMed Web of Science ®Google Scholar
• Ma X, Liu S, Zhang J, Dong M, Wang Y, Wang M, Xin Y. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol. 2020;20:10.
   PubMed Web of Science ®Google Scholar
• Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatol Baltim Md. 2018;67:123–133.
   PubMed Web of Science ®Google Scholar
• Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47–64.
   PubMed Web of Science ®Google Scholar
• Puri P, Sanyal AJ. The intestinal microbiome in nonalcoholic fatty liver disease. Clin Liver Dis. 2018;22:121–132.
   PubMed Web of Science ®Google Scholar
• Bibbò S, Ianiro G, Dore MP, Simonelli C, Newton EE, Cammarota G. Gut microbiota as a driver of inflammation in nonalcoholic fatty liver disease. Mediators Inflamm. 2018;2018:9321643.
   PubMed Web of Science ®Google Scholar
• Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–484.
   PubMed Web of Science ®Google Scholar
• Mar Rodríguez M, Pérez D, Javier Chaves F, Esteve E, Marin-Garcia P, Xifra G, Vendrell J, Jové M, Pamplona R, Ricart W, et al. Obesity changes the human gut mycobiome. Sci Rep. 2015;5:14600.
   PubMed Web of Science ®Google Scholar
• Sun S, Sun L, Wang K, Qiao S, Zhao X, Hu X, Chen W, Zhang S, Li H, Dai H, et al. The gut commensal fungus, Candida parapsilosis, promotes high fat-diet induced obesity in mice. Commun Biol. 2021;4:1–11.
   PubMed Web of Science ®Google Scholar
• Heisel T, Montassier E, Johnson A, Al-Ghalith G, Lin YW, Wei LN, Knights D, Gale CA. High-fat diet changes fungal microbiomes and interkingdom relationships in the murine gut. M Sphere. 2017;2: e00351-17.
   Google Scholar
• Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, Greve JW, Buurman WA, de Vos WM, Rensen SS. Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. Obesity. 2013;21:E607–615.
   PubMed Web of Science ®Google Scholar
• Chopyk DM, Grakoui A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders. Gastroenterology. 2020;159:849–863.
   PubMed Web of Science ®Google Scholar
• You N, Xu J, Wang L, Zhuo L, Zhou J, Song Y, Ali A, Luo Y, Yang J, Yang W, et al. Fecal fungi dysbiosis in nonalcoholic fatty liver disease. Obes Silver Spring Md. 2021;29:350–358.
   PubMed Web of Science ®Google Scholar
• Demir M, Lang S, Hartmann P, Duan Y, Martin A, Miyamoto Y, Bondareva M, Zhang X, Wang Y, Kasper P, et al. The fecal mycobiome in non-alcoholic fatty liver disease. J Hepatol. 2022;76:788–799.
   PubMed Web of Science ®Google Scholar
• Kamiński DM. Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments. Eur Biophys J. 2014;43:453–467.
   PubMed Web of Science ®Google Scholar
• Salyer ACD, Caruso G, Khetani KK, Fox LM, Malladi SS, David SA. Identification of adjuvantic activity of amphotericin B in a novel, multiplexed, poly-TLR/NLR high-throughput screen. PLos One. 2016;11:e0149848.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet. 2013;382:1587–1599.
   PubMed Web of Science ®Google Scholar
• Loftus EV, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, Jewell DA, Sandborn WJ. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91–96.
   PubMed Web of Science ®Google Scholar
• Pollheimer MJ, Halilbasic E, Fickert P, Trauner M. Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2011;25:727–739.
   PubMed Web of Science ®Google Scholar
• Chapman R, Cullen S. Etiopathogenesis of primary sclerosing cholangitis. World J Gastroenterol. 2008;14:3350–3359.
   PubMed Web of Science ®Google Scholar
• Muratori P, Muratori L, Guidi M, Maccariello S, Pappas G, Ferrari R, Gionchetti P, Campieri M, Bianchi FB. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol. 2003;132:473–476.
   PubMed Web of Science ®Google Scholar
• Rudolph G, Gotthardt D, Klöters-Plachky P, Kulaksiz H, Rost D, Stiehl A. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol. 2009;51:149–155.
   PubMed Web of Science ®Google Scholar
• Katt J, Schwinge D, Schoknecht T, Quaas A, Sobottka I, Burandt E, Becker C, Neurath MF, Lohse AW, Herkel J, et al. Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis. Hepatol Baltim Md. 2013;58:1084–1093.
   PubMed Web of Science ®Google Scholar
• Nakamoto N, Sasaki N, Aoki R, Miyamoto K, Suda W, Teratani T, Suzuki T, Koda Y, Chu PS, Taniki N, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol. 2019;4:492–503.
   PubMed Web of Science ®Google Scholar
• Lemoinne S, Kemgang A, Belkacem KB, Straube M, Jegou S, Corpechot C, Network SA, Chazouillères O, Housset C, Sokol H. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut. 2020;69:92–102.
   PubMed Web of Science ®Google Scholar
• Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I, et al. Fungal microbiota dysbiosis in IBD. Gut. 2017;66:1039–1048.
   PubMed Web of Science ®Google Scholar
• Rühlemann MC, Solovjeva MEL, Zenouzi R, Liwinski T, Kummen M, Lieb W, Hov JR, Schramm C, Franke A, Bang C. Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of trichocladium griseum and candida species. Gut. 2020;69:1890–1892.
   PubMed Web of Science ®Google Scholar
• Vasquez A, Zavasky D, Chow NA, Gade L, Zlatanic E, Elkind S, Litvintseva AP, Pappas PG, Perfect JR, Revankar S, et al. Management of an outbreak of exophiala dermatitidis bloodstream infections at an outpatient oncology clinic. Clin Infect Dis off Publ Infect Dis Soc Am. 2018;66:959–962.
   PubMed Web of Science ®Google Scholar
• Oztas E, Odemis B, Kekilli M, Kurt M, Dinc BM, Parlak E, Kalkanci A, Sasmaz N. Systemic phaeohyphomycosis resembling primary sclerosing cholangitis caused by exophiala dermatitidis. J Med Microbiol. 2009;58:1243–1246.
   PubMed Web of Science ®Google Scholar
• Hong KH, Kim JW, Jang SJ, Yu E, Kim EC. Liver cirrhosis caused by exophiala dermatitidis. J Med Microbiol. 2009;58:674–677.
   PubMed Web of Science ®Google Scholar
• Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the world health organization. J Clin Pathol. 1978;31:395–414.
   PubMed Web of Science ®Google Scholar
• Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838–851.
   PubMed Web of Science ®Google Scholar
• GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5:245–266.
   PubMed Web of Science ®Google Scholar
• Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28:26–42.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Liu EJ, Kheradman R, Fagan A, Heuman DM, White M, Gavis EA, Hylemon P, Sikaroodi M, Gillevet PM. Fungal dysbiosis in cirrhosis. Gut. 2018;67:1146–1154.
   PubMed Web of Science ®Google Scholar
• Zullo A, Hassan C, Ridola L, Lorenzetti R, Campo SM, Riggio O. Rifaximin therapy and hepatic encephalopathy: pros and cons. World J Gastrointest Pharmacol Ther. 2012;3:62–67.
   PubMedGoogle Scholar
• Chen Y, Chen Z, Guo R, Chen N, Lu H, Huang S, Wang J, Li L. Correlation between gastrointestinal fungi and varying degrees of chronic hepatitis B virus infection. Diagn Microbiol Infect Dis. 2011;70:492–498.
   PubMed Web of Science ®Google Scholar
• Guo R, Chen Z, Chen N, Chen Y. Quantitative real-time PCR analysis of intestinal regular fungal species in fecal samples from patients with chronic hepatitis B virus infection. Lab Med. 2010;41:591–596.
   Google Scholar
• Mou H, Yang F, Zhou J, Bao C. Correlation of liver function with intestinal flora, vitamin deficiency and IL-17A in patients with liver cirrhosis. Exp Ther Med. 2018;16:4082–4088.
   PubMed Web of Science ®Google Scholar
• Cui L, Morris A, Ghedin E. The human mycobiome in health and disease. Genome Med. 2013;5:63.
   PubMed Web of Science ®Google Scholar
• Ou TM, Huang HH, Hsieh TY, Chang WK, Chu HC, Hsu CH, Shih YL, Huang TY, Chen PJ, Lin HH. Liver cirrhosis as a predisposing factor for esophageal candidiasis. Adv Dig Med. 2014;1:86–91.
   Google Scholar
• Verma N, Roy A, Singh S, Pradhan P, Garg P, Singh M. Factors determining the mortality in cirrhosis patients with invasive candidiasis: a systematic review and meta-analysis. Med Mycol. 2022;60:myab069.
   Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primer. 2021;7:6.
   PubMed Web of Science ®Google Scholar
• IARC International Agency for Research on Cancer. GLOBOCAN 2018. 2020 [Accessed 2022 July 7]. http://gco.iarc.fr/today/home.
   Google Scholar
• Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61.
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L, Del Chierico F, Sanguinetti M, Morelli D, Paroni Sterbini F, Petito V, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatol Baltim Md. 2019;69:107–120.
   PubMed Web of Science ®Google Scholar
• Ren Z, Li A, Jiang J, Zhou L, Yu Z, Lu H, Xie H, Chen X, Shao L, Zhang R, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;68:1014–1023.
   PubMed Web of Science ®Google Scholar
• Kew MC. Aflatoxins as a cause of hepatocellular carcinoma. J Gastrointest Liver Dis JGLD. 2013;22:305–310.
   PubMed Web of Science ®Google Scholar
• Hamid AS, Tesfamariam IG, Zhang Y, Zhang ZG. Aflatoxin B1-induced hepatocellular carcinoma in developing countries: geographical distribution, mechanism of action and prevention. Oncol Lett. 2013;5:1087–1092.
   PubMed Web of Science ®Google Scholar
• Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007;26:2166–2176.
   PubMed Web of Science ®Google Scholar
• Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350:429–431.
   PubMed Web of Science ®Google Scholar
• Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, Wogan GN, Groopman JD. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, people’s republic of China. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 1994;3:3–10.
   Google Scholar
• Allen SJ, Wild CP, Wheeler JG, Riley EM, Montesano R, Bennett S, Whittle HC, Hall AJ, Greenwood BM. Aflatoxin exposure, malaria and hepatitis B infection in rural Gambian children. Trans R Soc Trop Med Hyg. 1992;86:426–430.
   PubMed Web of Science ®Google Scholar
• Turner PC, Mendy M, Whittle H, Fortuin M, Hall AJ, Wild CP. Hepatitis B infection and aflatoxin biomarker levels in Gambian children. Trop Med Int Health TM IH. 2000;5:837–841.
   PubMed Web of Science ®Google Scholar
• Groopman JD, Wang JS, Scholl P. Molecular biomarkers for aflatoxins: from adducts to gene mutations to human liver cancer. Can J Physiol Pharmacol. 1996;74:203–209.
   PubMed Web of Science ®Google Scholar
• Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26:144–152.
   PubMed Web of Science ®Google Scholar
• Ahn JY, Jung EY, Kwun HJ, Lee CW, Sung YC, Jang KL. Dual effects of hepatitis B virus X protein on the regulation of cell-cycle control depending on the status of cellular p53. J Gen Virol. 2002;83:2765–2772.
   PubMed Web of Science ®Google Scholar
• Madden CR, Finegold MJ, Slagle BL. Altered DNA mutation spectrum in aflatoxin b1-treated transgenic mice that express the hepatitis B virus x protein. J Virol. 2002;76:11770–11774.
   PubMed Web of Science ®Google Scholar
• Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, Pinkert CA, Brinster RL, Palmiter RD. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell. 1989;59:1145–1156.
   PubMed Web of Science ®Google Scholar
• Liu Z, Li Y, Li C, Lei G, Zhou L, Chen X, Jia X, Lu Y. Intestinal Candida albicans promotes hepatocarcinogenesis by up-regulating NLRP6. Front Microbiol. 2022;13:812771.
   PubMed Web of Science ®Google Scholar
• Zhou L, Ding L, Yin P, Lu X, Wang X, Niu J, Gao P, Xu G. Serum metabolic profiling study of hepatocellular carcinoma infected with hepatitis B or hepatitis C virus by using liquid chromatography-mass spectrometry. J Proteome Res. 2012;11:5433–5442.
   PubMed Web of Science ®Google Scholar
• Fujiwara N, Nakagawa H, Enooku K, Kudo Y, Hayata Y, Nakatsuka T, Tanaka Y, Tateishi R, Hikiba Y, Misumi K, et al. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut. 2018;67:1493–1504.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Takaki A, Tsuzaki R, Yasunaka T, Koike K, Shimomura Y, Seki H, Matsushita H, Miyake Y, Ikeda F, et al. L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway. PLos One. 2014;9:e100627.
   PubMed Web of Science ®Google Scholar
• Levy M, Thaiss CA, Zeevi D, Dohnalova L, Zilberman-Schapira G, Mahdi JA, David E, Savidor A, Korem T, Herzig Y, et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell. 2015;163:1428–1443.
   PubMed Web of Science ®Google Scholar
• Li R, Zhu S. NLRP6 inflammasome. Mol Aspects Med. 2020;76:100859.
   PubMed Web of Science ®Google Scholar
• Ansari F, Alian Samakkhah S, Bahadori A, Jafari SM, Ziaee M, Khodayari MT, Pourjafar H. Health-promoting properties of Saccharomyces cerevisiae var. boulardii as a probiotic; characteristics, isolation, and applications in dairy products. Crit Rev Food Sci Nutr. 2021;0:1–29.
   Google Scholar
• Yu L, Zhao X, Cheng M, Yang GZ, Wang B, Liu HJ, Hu YX, Zhu LL, Zhang S, Xiao ZW, et al. Saccharomyces boulardii administration changes gut microbiota and attenuates D-Galactosamine-induced liver injury. Sci Rep. 2017;7:1359.
   PubMed Web of Science ®Google Scholar
• Everard A, Matamoros S, Geurts L, Delzenne NM, Cani PD. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. mBio. 2014;5:e01011–01014.
   PubMed Web of Science ®Google Scholar
• Liu YT, Li YQ, Wang YZ. Protective effect of saccharomyces boulardii against intestinal mucosal barrier injury in rats with nonalcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi Zhonghua Ganzangbing Zazhi Chin J Hepatol. 2016;24:921–926.
   PubMedGoogle Scholar
• Huang J, Ou Y, Yew TWD, Liu J, Leng B, Lin Z, Su Y, Zhuang Y, Lin J, Li X, et al. Hepatoprotective effects of polysaccharide isolated from Agaricus bisporus industrial wastewater against CCl₄-induced hepatic injury in mice. Int J Biol Macromol. 2016;82:678–686.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zheng D, Su L, Wang Q. Protective effect of polysaccharide from Agaricus bisporus in Tibet area of China against tetrachloride-induced acute liver injury in mice. Int J Biol Macromol. 2018;118:1488–1493.
   PubMed Web of Science ®Google Scholar
• Li S, Li J, Zhang J, Wang W, Wang X, Jing H, Ren Z, Gao Z, Song X, Gong Z, et al. The antioxidative, antiaging, and hepatoprotective effects of alkali-extractable polysaccharides by Agaricus bisporus. Evid-Based Complement Altern Med ECAM. 2017;2017:7298683.
   PubMed Web of Science ®Google Scholar
• Duan Z, Zhang Y, Zhu C, Wu Y, Du B, Ji H. Structural characterization of phosphorylated pleurotus ostreatus polysaccharide and its hepatoprotective effect on carbon tetrachloride-induced liver injury in mice. Int J Biol Macromol. 2020;162:533–547.
   PubMed Web of Science ®Google Scholar
• Fernández-Pacheco P, Pintado C, Briones Pérez A, Arévalo-Villena M. Potential probiotic strains of saccharomyces and non-saccharomyces: functional and biotechnological characteristics. J Fungi. 2021;7:177.
   Web of Science ®Google Scholar
• Santino I, Alari A, Bono S, Teti E, Marangi M, Bernardini A, Magrini L, Di Somma S, Teggi A. Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of clostridium difficile colitis with a probioticum. Int J Immunopathol Pharmacol. 2014;27:143–146.
   PubMed Web of Science ®Google Scholar
• Cesaro S, Chinello P, Rossi L, Zanesco L. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with saccharomyces boulardii. Support Care Cancer off J Multinatl Assoc Support Care Cancer. 2000;8:504–505.
   PubMed Web of Science ®Google Scholar